Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer

Gynecologic Oncology

Volumn 112, Issue 1, 2009, Pages 275-281

  Muggia, Franco ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Carboplatin; Cisplatin; DNA repair; Intraperitoneal therapy; Ovarian cancer; Oxaliplatin

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; AZD 2281; BEVACIZUMAB; BORTEZOMIB; C MET INHIBITOR; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOXORUBICIN; ENZYME INHIBITOR; ERLOTINIB; FLUOROURACIL; GEMCITABINE; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; INSULIN LIKE GROWTH FACTOR 1 INHIBITOR; MITOMYCIN C; MLN 8237; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PF 573271; PLATINUM DERIVATIVE; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; TOPOISOMERASE 1 INHIBITOR; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BONE MARROW SUPPRESSION; CANCER THERAPY; COLON CANCER; CONTINUOUS INFUSION; DNA REPAIR; DRUG EFFICACY; DRUG MECHANISM; GYNECOLOGIC CANCER; HUMAN; NEUROPATHY; ONCOGENE; OTOTOXICITY; OVARY CANCER; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANIMALS; FEMALE; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS;

EID: 57649101120     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.09.034     Document Type: Review

References (73)

1. Muggia F.M., Rozencweig M., Bono V.H., and Jacobs Jr. E.M. Cisdichlorodiammineplatin II: The trail from an inert electrode to a therapeutic solution. Cancer Treat. Rep. 63 (1979) 1431-1432
2. Rosenberg B. Cisplatin: its history and possible mechanisms of action. In: Prestayko A.W., Crooke S.T., and Carter S.K. (Eds). Cisplatin: Current status and new developments (1980), Academic Press, New York 9-20
3. In: Connors T.A., and Roberts J.J. (Eds). Platinum coordination complexes in cancer chemotherapy (1974), Springer-Verlag, Heidelberg
4. Rozencweig M., Von Hoff D.D., Slavik M., and Muggia F.M. Cis-diamminedichloroplatinum II (DDP): a new anticancer drug. Ann. Intern. Med. 86 (1977) 803-812
5. Rosenberg B. Cisplatin. J. Clin. Hematol. Oncol. (Wadley. Bulletin) 7 (1977) 817-827
6. In: Hacker M.P., Double E.B., and Krakoff I.H. (Eds). Platinum coordination complexes in cancer chemotherapy (1984), Martinus Nihjoff Publishers, Boston 1-775
7. In: Nicolini M. (Ed). Platinum and other metal coordination compounds in cancer chemotherapy (1988), Martinus Nihjoff Publishers, Boston
8. In: Howell S.B. (Ed). Platinum and other metal coordination compounds in cancer chemotherapy (1991), Plenum Press, New York 1-546
9. In: Pinedo H.M., and Schornagel J.H. (Eds). Platinum and other metal coordination compounds in cancer chemotherapy (1996), Plenum Press, New York 1-357
10. In: Kelland L.R., and Farrell N.P. (Eds). Platinum-based drugs in cancer therapy (2000), Humana Press, Totowa, NJ 1-341
11. Muggia F.M., and Farrell N. Platinum coordination compounds in cancer chemotherapy. Crit. Rev. Oncol. Hematol. 51 (2005) 1-2
12. In: Bonetti A., Leoni R., Howell S., and Muggia F. (Eds). Platinum and other metal coordination compounds in cancer chemotherapy (2008), Humana Press
13. Muggia F.M., and Fojo T. Platinums: extending their therapeutic spectrum. J. Chemotherapy 4 suppl 16 (2004) 77-82
14. Guggenheim ER, Lee NS, Lippard SJ. Photo-cross-linking and identification of proteins that bind to platinum-modified DNA in cell extracts. Abstracts of the 10th International Symposium of Platinum Coordination Compounds in Cancer Chemotherapy (Abstract p32).
15. Rottenberg S., Nygren A.O., Pajic M., van Leeuwen F.W., van der Heijden I., van de Wetering K., Liu X., de Visser K.E., Guilhuijs K.G., van Tellingen O., Schouten J.P., Jonkers J., and Borst P. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 12117-12122
16. Liu X., Rottenberg S., Pajic M., et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 12111-12116
17. Borst P., Rottenberg S., and Jonkers J. How do real tumors become resistant to cisplatin. Cell Cycle 7 (2008) 1353-1359
18. Swisher E.M., Karlan B., et al. Secondary BRCA1 mutations in BRCA1 mutated ovarian cancer with platinum resistance. Cancer Res. 68 (2008) 2581-2586
19. Sakai W., Swisher E.M., Karlan B.Y., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451 (2008) 1116-1120
20. Fong P.C., Boss D.S., Carden C.P., Roelvink M., De Greve J., Gourley C.M., et al. AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study. J. Clin. Oncol. 20 Suppl: abstr 5510 (2008)
21. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 7035 (2005) 913-917
22. Smith L.M., Willmore E., Austin C.A., and Curtin N.J. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin. Cancer Res. 11 (2005) 8449-8457
23. Rowinsky E.K., Kaufmann S.H., Baker S.D., Grochow L.B., Chen T.L., Peereboom D., et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J. Clin. Oncol. 14 (1996) 3074-3084
24. Romanelli S., Perego P., Pratesi G., Carenini N., Tortoreto M., and Zunino F. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother. Pharmacol. 41 5 (1998) 385-390
25. Hochster H., Chen T., Lu J.M., et al. Phase I and pharmacokinetic study of oxaliplatin combined with continuous infusion topotecan in ovarian cancer. Gynecol. Oncol. (2008)
26. Tanaka T., Kurose A., Huang X., Dai W., and Darzynkiewicz Z. ATM activation and histone H2AX phosphorylation as indicators of DNA damage by DNA topoisomerase I inhibitor topotecan and during apoptosis. Cell. Prolif. 39 (2006) 49-60
27. Danford A.J., Wang D., Wang Q., Tullius T.D., and Lippard S.J. Platinum anticancer drug damage enforces a particular rotational setting of DNA in nucleosomes. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 12311-12316
28. Holzer A.K., Samimi G., Katano K., et al. The cooper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol. Pharmacol. 66 (2004) 817-823
29. Safaei R., and Howell S.B. Copper transporters regulate the cellular pharmacology and sensitivity to platinum drugs. Crit. Rev. Oncolo. Hematol. 53 (2005) 13-23
30. Holzer A.K., Katano K., Klomp L.W., and Howell S.B. Cisplatin rapidly down-regulates its own influx transporter hctr1 in cultured human ovarian carcinoma cells. Clin. Cancer Res. 10 (2004) 6744-6749
31. Jonker J.W., and Schinkel A.H. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J. Pharmacol. Exp. Ther. 308 (2004) 2-9
32. Noorhuis P, Lann AC, Losekoot N, van de Born K, Peters GJ. Oxaliplatin accumulation and DNA adduct formation in oxaliplatin resistant colorectal and ovarian cell lines: relation with mRNA expression of transport and DNA repair genes. Abstracts of the 10th International Symposium of Platinum Coordination Compounds in Cancer Chemotherapy (Abstract p93).
33. th International Symposium of Platinum Coordination Compounds in Cancer Chemotherapy (Abstract p117).
34. th International Symposium of Platinum Coordination Compounds in Cancer Chemotherapy (Abstract p108)
35. th International Symposium of Platinum Coordination Compounds in Cancer Chemotherapy (Abstract p22).
36. Dembo A. Controversy over combination chemotherapy in advanced ovarian cancer: what we learn from reports of mature data. J. Clin. Oncol. 6 (1983) 431-435
37. McGuire W.P., Hoskins W.J., Brady M.F., et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 13 (1995) 1589-1599
38. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
39. Muggia F.M. Sequential single agents as first-line chemotherapy in ovarian cancer: a strategy derived from the results of GOG-132. Int. J. Gynecol. Cancer 13 suppl 2 (2003) 156-162
40. Parmar M.K., Ledermann J.A., Colombo N., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
41. Stordal B., Pavlakis N., and Davey R. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev. 33 (2007) 688-703
42. Muggia F.M. Hexamethylmelamine in platinum resistant ovarian cancer: how active (Editorial). Gynecol. Oncol. 47 (1992) 279-281
43. Harries M., and Gore M. Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol. 3 9 (2002) 537-545
44. Bookman M.A. First-line randomized trials: revisiting the Ptolemaic universe. Int. J. Gynecol. OCancer. 18 suppl 1 (2008) 47-52
45. Markman M., Liu P.Y., Wilczynski S., et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol. 21 (2003) 2460-2465
46. Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacave A.J., et al. AGO-OVAR; NCIC CTG; EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24 (2006) 4699-4707
47. Ferrero J.M., Weber B., Geay J.F., Lepille D., Orfeuvre H., Combe M., et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann. Oncol. 18 2 (2007) 263-268 Feb
48. Hochster H.S., Plimack E.R., Mandeli J., et al. Prolonged topotecan infusion with cisplatin in first-line treatment of ovarian cancer: an NYGOG and ECOG study. Gynecol. Oncol. 100 (2006) 324-329
49. Alberts D.S., Liu P.Y., Hannigan E.V., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335 (1996) 1950-1955
50. Markman M., Bundy B.N., Alberts S., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19 (2001) 1-7
51. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
52. Markman M. What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?. Int. J. Gyencol. Cancer 18 suppl 1 (2008) 36-39
53. Trimble E.L., and Christian M.C. National Cancer Institute - United States strategy regarding intraperitoneal chemotherapy for ovarian cancer. Int. J. Gyencol. Cancer 18 suppl 1 (2008) 26-28
54. Fujiwara K. Can carboplatin replace cisplatin for intraperitoneal use?. Int. J. Gyencol. Cancer 18 suppl 1 (2008) 29-32
55. Howell S.B. Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer. Int. J. Gyencol. Cancer 18 suppl 1 (2008) 20-25
56. Elias D., Bonnay M., Pouizillou M., et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann. Oncol. 13 (2002) 262-272
57. Stordal B., Pavlakis N., and Davey R. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systemic review. Cancer Treat. Rev. 33 (2007) 347-357
58. Delaloge S., Laadem A., Tamma A., Chouaki N., Cvitkovic E., Pautier P., et al. Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer. Am. J. Clin. Oncol. 23 (2000) 569-574
59. Faivre S., Kalla S., Cvitkovic E., Bourdon O., Hauterville D., Dourte L.M., et al. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. Ann. Oncol. 10 (1999) 1125-1128
60. Viens P., Petit T., Yovine A., Bougnoux P., Deplanque G., Cottu P.H., et al. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann. Oncol. 17 (2006) 429-436
61. Nicoletto M.O., Falci C., Pianalto D., Artioli G., Azzoni P., De Masi G., et al. Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Gynecol. Oncol. 10 (2006) 318-323
62. Raspagliesi F., Zanaboni F., Veccione F., Hanozet F., Scollo P., Ditto A., et al. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane. Oncology 67 (2004) 376-381
63. Faivre S., Le Chevalier T., Monnerat C., Lokiec F., Novello S., Taieb J., et al. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann. Oncol. 13 (2002) 1479-1489
64. Pectasides D., Pectasides M., Farmakis D., Gaglia A., Koumarianou M., Nikolaou M., et al. Oxaliplatin plus high-dose leucorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Gynecol. Oncol. 95 (2004) 165-172
65. Hochster H., Chen T.T., Lu J.M., Hills D., Sorich J., Escalon J., et al. Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. Gynecol. Oncol. 108 3 (2008) 500-504
66. Obeid M., Tesniere A., Panaretakis T., et al. Ecto-calreticulin in immunogenic chemotherapy. Immunol. Rev. 220 (2007) 22-34 Dec
67. Apetoh L., Ghiringhelli F., and Zvitvogel L. Calreticulin dictates the immunogenicity of anti-cancer chemotherapy and radiotherapy. Med. Sci. 23 (2007) 257-258
68. Szotek P.P., Pieretti-Vanmarcke R., Masiakos P.T., et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc. Natl. Acad. Sci. U. S. A. 103 30 (2006) 11154-11159 Jul 25
69. Dinulescu D.M., Ince T.A., Quade B.J., Shafer S.A., Crowley D., and Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nature Med. 11 (2005) 63-70
70. Burger R.A., Sill M., Monk B.J., et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 25 (2007) 5615-5671
71. S.A. Cannistra, U. Matulonis, R. Penson et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25:5180-5186
72. Garcia A.A., Hirte J., Fleming G., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital Phase II consortia. J. Clin. Oncol. 26 (2008) 76-82
73. Azad N.S., Posadas E.M., Kwitkowski V.E., Steinberg S.M., Jain L., Annunziata C.M., et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol. 26 22 (2008) 3709-3714